Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2026
  • July
  • Page 35
new-e25-million-bioreliance-testing-facility-opens-at-merck-kgaa-global-headquarters-in-germany
Posted inGenetics

New €25 Million BioReliance Testing Facility Opens at Merck KGaA Global Headquarters in Germany

July 20, 2026
The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical…
Read More
Posted inBiotechnology

Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trial

July 20, 2026
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study…
Read More
Posted inMedical Technology

Tempus buys out cancer genomics partner Personalis in $1.5 billion deal

July 20, 2026
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed…
Read More
Posted inBiotechnology

Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds

July 20, 2026
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million…
Read More
Posted inBiotechnology

BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’

July 20, 2026
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercomputer for drug R&D, according…
Read More
stockwatch:-lilly’s-up-to-$3.8b-deal-for-ataibeckley-a-good-trip-for-psychedelic-drugs,-analysts-and-investors-agree
Posted inGenetics

StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

July 19, 2026
[Credit: wildpixel / 1306005226 / iStock / Getty Images Plus] It wasn’t too long ago that biopharma giants stayed away…
Read More
Posted inBiotechnology

Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax

July 19, 2026
Latigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain…
Read More
sleep-quality-links-synergistically-with-frailty-to-increase-cardiometabolic-multimorbidity-in-elderly-chinese
Posted inBiotechnology

Sleep Quality Links Synergistically with Frailty to Increase Cardiometabolic Multimorbidity in Elderly Chinese

July 19, 2026
Sleep has long been suspected to influence how aging bodies manage multiple chronic conditions, but the interplay between rest quality…
Read More
Posted inBiotechnology

Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC funds

July 19, 2026
Geopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an industry leader has told Fierce, even as the…
Read More
cognitive-reserve-helps-older-adults-resist-frailty-and-recover-better
Posted inBiotechnology

Cognitive reserve helps older adults resist frailty and recover better

July 19, 2026
A new study reported in BMC Geriatrics spotlights cognitive reserve—the brain’s lifelong ability to adapt—as a potential resilience factor for…
Read More

Posts pagination

Previous page 1 … 33 34 35 36 37 … 104 Next page

Privacy Policy    Terms

Scroll to Top